Compass

Overview of Proposed Rule Changes to “Safe Harbor” Regulation

February 27, 2019   |   By Brian Duffant

Health and Human Services (HHS) is proposing to eliminate safe harbor protection for manufacturer reductions in price on prescription pharmaceutical products to Medicare Part D plans, PBM’s, and Medicaid Managed Care Organizations.

In conjunction with this amendment, HHS is proposing new safe harbor protections which would protect manufacturer point-of-sale (POS)…

MORE

The Institute for Clinical and Economic Review, a non-profit institute evaluates the cost-effectiveness of drugs, medical devices, medical procedures, and diagnostics. The Institute for Clinical and Economic Review has published multiple assessments of healthcare technologies which provide a volume of evidence to better understand the quantitative conclusions by each evaluation…

MORE

March 24, 2018 | Lopamudra Das, Brian Duffant, Courtney Coles

Chimeric Antigen Receptor T-cell (CAR-T) therapies represent a breakthrough in cancer care due to the significant clinical response induced in patients who do not respond to currently available treatments. In 2017, two CAR-T therapies were approved by the FDA –…

MORE

US Market Access – Key Considerations in a Changing Environment

November 1, 2017   |   By Brian Duffant

Many life science manufacturers employ a payer size and control strategy in the US market. While this continues to be viable model, changes in formulary and benefit design result in local-level access variation. This suggests that alternative strategic approaches are important to consider when manufacturers engage in market access planning.

MORE

New drug coverage policies provide guidance around a payer’s coverage of new drugs in the time period between FDA approval and P&T committee review. As these policies proliferate, manufacturers may find initial new drug launch access to be more limited than anticipated.

Key Findings

Commercial and Medicare Part D payers…

MORE

Medicare Part D Direct & Indirect Remuneration

September 1, 2017   |   By Brian Duffant

Payers who offer Medicare Part D plans may receive additional compensation after the point-of-sale. These funds are known as Direct & Indirect Remuneration (DIR), and account for growing levels of disparity between Part D gross and net drug costs. As DIR is primarily composed of manufacturer rebates on select drugs,…

MORE

Track & share BPS insights

LinkedIn

Our knowledge is your insight

Get grounded and stay informed. Sign up to receive our educational primers, insights, research papers and presentations.

Recent Posts

Overview of Proposed Rule Changes to “Safe Harbor” Regulation
A Snapshot of the Conclusions on Long-term Value of Healthcare Treatments Conducted by the Institute for Clinical and Economic Review Group
CAR-T Commercial Market Access Brief – A Review of Initial Brand Access at Select US Payers
US Market Access – Key Considerations in a Changing Environment
Emerging Barriers to Launch Access – the Impact of New Drug Coverage Policies
Medicare Part D Direct & Indirect Remuneration